The European Commission on Wednesday 22 April cleared the proposed merger between global pharmaceutical company Mylan of the Netherlands and Upjohn of China, a division of Pfizer that operates its 'off-patent branded and generic established medicines' business. The decision is subject to the divestment of Mylan's business for certain generic medicines.
Margrethe Vestager, Executive Vice President in charge of Competition Policy, said "Our decision ensures that the merger between Mylanand...